John A. Hill, III and Susan Hill v. Steven N. Rhinehart, M.D. and Fort Wayne Medical Oncology and Hematology, Inc. John F. Csicsko, M.D. and David P. Lloyd, M.D., as Individuals

CourtIndiana Court of Appeals
DecidedOctober 15, 2015
Docket02A03-1405-CT-146
StatusPublished

This text of John A. Hill, III and Susan Hill v. Steven N. Rhinehart, M.D. and Fort Wayne Medical Oncology and Hematology, Inc. John F. Csicsko, M.D. and David P. Lloyd, M.D., as Individuals (John A. Hill, III and Susan Hill v. Steven N. Rhinehart, M.D. and Fort Wayne Medical Oncology and Hematology, Inc. John F. Csicsko, M.D. and David P. Lloyd, M.D., as Individuals) is published on Counsel Stack Legal Research, covering Indiana Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
John A. Hill, III and Susan Hill v. Steven N. Rhinehart, M.D. and Fort Wayne Medical Oncology and Hematology, Inc. John F. Csicsko, M.D. and David P. Lloyd, M.D., as Individuals, (Ind. Ct. App. 2015).

Opinion

Oct 15 2015, 9:08 am

ATTORNEYS FOR APPELLANTS ATTORNEYS FOR APPELLEES Brian J. Hurley C. Christopher Dubes Timothy Krsak Barrett & McNagny, LLP Douglas Koeppen & Hurley Fort Wayne, Indiana Valparaiso, Indiana Karl L. Mulvaney Nana Quay-Smith Jessica Whelan Bingham Greenebaum Doll, LLP Indianapolis, Indiana Mark W. Baeverstad Andrew L. Palmison Rothberg Logan & Warsco Fort Wayne, Indiana

IN THE COURT OF APPEALS OF INDIANA

John A. Hill, III and Susan Hill, October 15, 2015

Appellants-Plaintiffs, Court of Appeals Case No. 02A03-1405-CT-146 v. Appeal from the Allen Superior Court

Steven N. Rhinehart, M.D. and The Honorable Stanley A. Levine, Judge Fort Wayne Medical Oncology and Hematology, Inc.; John F. Cause No. 02D01-0908-CT-318 Csicsko, M.D. and David P. Lloyd, M.D., as Individuals and Cardiovascular Associates of Northeastern Indiana, LLC, a Professional Corporation; and Thomas P. Ryan, D.O.,

Court of Appeals of Indiana | Opinion 02A03-1405-CT-146 | October 15, 2015 Page 1 of 26 Appellees-Defendants.

Riley, Judge.

STATEMENT OF THE CASE

[1] Appellants-Plaintiffs, John A. Hill (Hill) and Susan Hill, appeal the trial court’s

judgment in favor of Steven N. Rhinehart, M.D. (Dr. Rhinehart) and Fort

Wayne Medical Oncology and Hematology, Inc.; John F. Csicsko, M.D. (Dr.

Csicsko) and David P. Lloyd, M.D. (Dr. Lloyd), as individuals, and

Cardiovascular Associates of Northeastern Indiana, LLC, a professional

corporation; and Thomas P. Ryan, D.O. (Dr. Ryan).

[2] We affirm.

ISSUES

[3] Hill raises three issues on appeal, which we restate as follows:

(1) Whether the trial court properly granted judgment on the evidence in

favor of Dr. Lloyd and Dr. Csicsko;

(2) Whether Hill was prevented from pursuing a theory of joint and several

liability against all physicians by the entry of the judgment on the

evidence against two of the physicians; and

Court of Appeals of Indiana | Opinion 02A03-1405-CT-146 | October 15, 2015 Page 2 of 26 (3) Whether the trial court abused its discretion in tendering Jury

Instruction No. 23 and instructing the jury that physicians are not liable

for an error in diagnosis or treatment when exercising reasonable care.

FACTS AND PROCEDURAL HISTORY

[4] On December 6, 1999, Hill was admitted to Parkview Memorial Hospital

(Parkview) for a cardiac catheterization related to angina pain. Dr. Ryan, a

board-certified cardiologist, performed the procedure, which revealed severe

coronary artery disease with multiple blockages of two main coronary arteries.

Because of the severity of the disease and Hill’s risk of death from sudden heart

attack, Dr. Ryan recommended immediate coronary artery bypass surgery for

the following day. On December 7, 1999, Dr. Lloyd, a board-certified vascular

surgeon, executed Hill’s coronary bypass surgery. Hill was given the standard

dose of 27,000 units of Heparin, “an anti-coagulant, used to thin the blood,”

which helped to “keep the blood flowing through the heart pump.” (Transcript

pp. 265, 292). He further received 5,000 units of Heparin subcutaneously twice

a day until December 9, 1999. The coronary bypass surgery was pronounced a

success and Hill was moved into the intensive care unit for recovery.

[5] As his recovery began, Hill manifested numerous complications. Immediately

following surgery, Hill experienced a “natural drop in platelets 1 as a result of

1 Platelets are cell-based mechanisms that “recognize that there’s been an injury and will aggregate at that site of injury” and form clots. (Tr. p. 266).

Court of Appeals of Indiana | Opinion 02A03-1405-CT-146 | October 15, 2015 Page 3 of 26 the surgery” because the “heart/lung bypass machine [used during surgery]

simply ‘chews up’ platelets.” (Tr. pp. 636, 683). Over the following day, Dr.

Ryan did not see the rebound from the low platelet count that he was expecting

and, as a result, on December 9, 1999, he entered an order to “[s]top all

subcutaneous Heparin.” (Tr. p. 637). At that point, Dr. Ryan suspected Hill to

be suffering from Heparin-Induced Thrombocytopenia (HIT), which is a rare

“immune mediated response to the presence of the Heparin antigen in the

body.” (Tr. p. 639). Usually, HIT manifests itself “about five to ten days after

exposure to the Heparin.” (Tr. p. 278). It “is an uncommon problem” and

“mimics many other disease processes. It’s very, very difficult to diagnose.”

(Tr. p. 1468). 2 By discontinuing all Heparin—which was the recommended

standard of care for treatment of HIT in 1999—Dr. Ryan expected to see “a

slow rise in the platelet count back to its normal levels within three to five

days.” (Tr. p. 640). Hill was not administered a non-Heparin anticoagulant as

a replacement medicine, even though a non-Heparin option, Refludan, was

available at Parkview. However, unbeknownst to Dr. Ryan, Hill continued to

receive a minimal dose of Heparin because of Parkview’s protocol that

prescribed “Heparin flushes” of the IV lines. (Tr. pp. 649-50).

2 In fact, during the early days of the disease in the 1980s, “many clinicians did not believe that HIT existed or HITT.” (Tr. p. 1458). It was not until the late ‘90s and early 2000s, that the medical community “started to formulate both diagnostic criteria that everybody accepted as reasonable and therapeutic modalities that were reasonable.” (Tr. p. 1459).

Court of Appeals of Indiana | Opinion 02A03-1405-CT-146 | October 15, 2015 Page 4 of 26 [6] Dr. Ryan’s anticipated bounce in platelet counts never occurred. Instead, Hill

developed life-threatening complications, including Adult Respiratory Distress

Syndrome (ARDS), Thrombocytopenia, 3 failure to wean from the ventilator,

Moraxella infection in his lungs, high fevers, sepsis, and extreme swelling

throughout his body. Based on this “constellation of symptoms” on December

13, 1999, Dr. Ryan believed Hill to be suffering from Disseminated

Intravascular Coagulopathy (DIC), which is “an extremely serious condition

manifested by formation of clots in blood vessels coupled at the same time with

the fall in the patient’s platelet count.” (Tr. pp. 701, 685). However, due to the

eighty percent drop in platelet count combined with a significant swelling of

Hill’s left arm, Hill’s medical expert, Harry Jacob, M.D. (Dr. Jacob), testified

that, at this point Hill’s HIT had developed a Thrombosis component (HITT) 4

and Refludan, the non-Heparin anticoagulant, should have been prescribed. In

1999, Refludan was a newly approved drug which was “not strongly supported

by the medical community” as it could cause severe “bleeding into the brain

tissue” and no reversal agent existed. (Tr. pp. 1479, 1480). “Refludan was

[later] taken off the market because its safety profile did not match what current

FDA standards would require.” (Tr. p. 1481).

3 Thrombocytopenia indicates a low platelet count. When a patient’s platelet count drops too low, he is at great risk of bleeding to death. (See Tr. pp. 1497-98). 4 In HITT patients, Heparin, which is given to prevent clotting, has the opposite effect: it activates the platelets’ clotting factor, causing the platelets to aggregate in clumps in the blood vessels. As a result, HITT decreases the patient’s blood platelet levels while simultaneously causing potentially fatal thrombosis. (See Tr. pp. 266-69).

Court of Appeals of Indiana | Opinion 02A03-1405-CT-146 | October 15, 2015 Page 5 of 26 [7] Throughout the day on December 13, 1999, Hill continued to experience a

Free access — add to your briefcase to read the full text and ask questions with AI

Related

LaPORTE COMMUNITY SCHOOL CORP. v. Rosales
963 N.E.2d 520 (Indiana Supreme Court, 2012)
Cavens v. Zaberdac
849 N.E.2d 526 (Indiana Supreme Court, 2006)
Wal-Mart Stores, Inc. v. Wright
774 N.E.2d 891 (Indiana Supreme Court, 2002)
Dahlberg v. Ogle
373 N.E.2d 159 (Indiana Supreme Court, 1978)
Terre Haute Regional Hospital, Inc. v. El-Issa
470 N.E.2d 1371 (Indiana Court of Appeals, 1984)
Johnson v. Naugle
557 N.E.2d 1339 (Indiana Court of Appeals, 1990)
Blocher v. DeBartolo Properties Management, Inc.
760 N.E.2d 229 (Indiana Court of Appeals, 2001)
Carrier Agency, Inc. v. Top Quality Building Products, Inc.
519 N.E.2d 739 (Indiana Court of Appeals, 1988)
Weller v. MacK Trucks, Inc.
570 N.E.2d 1341 (Indiana Court of Appeals, 1991)
Schultheis v. Franke
658 N.E.2d 932 (Indiana Court of Appeals, 1995)
Marquez v. Mayer
727 N.E.2d 768 (Indiana Court of Appeals, 2000)
Csicsko v. Hill
808 N.E.2d 80 (Indiana Court of Appeals, 2004)
Levee v. Beeching
729 N.E.2d 215 (Indiana Court of Appeals, 2000)
Miller Ex Rel. Miller v. Memorial Hospital of South Bend, Inc.
679 N.E.2d 1329 (Indiana Supreme Court, 1997)
Canfield v. Sandock
563 N.E.2d 1279 (Indiana Supreme Court, 1990)
Fall v. White
449 N.E.2d 628 (Indiana Court of Appeals, 1983)
Flagg v. McCann Corp.
498 N.E.2d 76 (Indiana Court of Appeals, 1986)
St. Anthony Medical Center, Inc. v. Smith
592 N.E.2d 732 (Indiana Court of Appeals, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
John A. Hill, III and Susan Hill v. Steven N. Rhinehart, M.D. and Fort Wayne Medical Oncology and Hematology, Inc. John F. Csicsko, M.D. and David P. Lloyd, M.D., as Individuals, Counsel Stack Legal Research, https://law.counselstack.com/opinion/john-a-hill-iii-and-susan-hill-v-steven-n-rhinehart-md-and-fort-indctapp-2015.